G Sachs Assigns Buy Rating to INNOVENT BIO Following Strengthened Long-term Collaboration with Eli Lilly
Strategic Collaboration: INNOVENT BIO has partnered with Eli Lilly to enhance the global development of innovative oncology and immunology drugs, involving an upfront payment of USD 350 million and potential milestone payments of up to USD 8.5 billion.
Market Analysis: Goldman Sachs reports that INNOVENT BIO's stock is currently undervalued, with a target price of HKD 102.85, based on a risk-adjusted discounted cash flow analysis, despite a high market-implied cost of capital.
Trade with 70% Backtested Accuracy
Analyst Views on 01801
About the author
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
HSI Rises by 155 Points Driven by Surge in AI and Pharmaceutical Stocks
Market Performance: The HSI rose by 155 points (0.6%) to close at 27,183, with a total market turnover of HKD234.04 billion. The HSCEI and HSTECH also saw gains, closing at 9,242 and 5,451 respectively.
Tech Stock Movements: Major tech stocks like TENCENT and MEITUAN-W experienced declines of 1.6% and 2.5%, while KUAISHOU-W, JD-SW, and BABA-W saw increases between 1.6% and 1.9%.
AI and Pharma Stocks Surge: AI stocks such as UNISOUND and INSILICO rose significantly, with KNOWLEDGE ATLAS jumping 14.8% after JPMorgan initiated coverage. Pharma stocks also performed well, with CSPC PHARMA and INNOVENT BIO gaining between 4.7% and 5.5%.
Chip Sector Performance: SMIC gained 1.7%, while HUA HONG SEMI dipped 1.2%. Other chip-related stocks like INNOSCIENCE and BIREN TECH saw notable increases, with INNOSCIENCE rising 6.9%.
<Daily Summary> HSI Ends at 27,183, Gaining 155 Points; HSTI Finishes at 5,451, Up 33 Points; CSPC PHARMA Surges Over 5%; ZTO EXPRESS-W, WH GROUP, BOC HONG KONG, WHARF REIC, and HANG LUNG PPT Reach New Peaks; Market Activity Increases
Market Performance: The Hang Seng Index (HSI) rose by 155 points (0.6%) to close at 27,183, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains, with market turnover reaching $234.04 billion.
Active Heavyweights: Notable movements included Meituan down 2.5%, Alibaba up 1.6%, Tencent down 1.6%, and Xiaomi up 1.1%, with significant short selling activity across these stocks.
Top Gainers: CSPC Pharma, Innovent Bio, and Pop Mart were among the top gainers, with CSPC Pharma increasing by 5.5% and Pop Mart by 4.9%, while New Oriental saw a decline of 4.4%.
High Performers in HSMI & HSSI: China Literature surged by 15.4%, Vobile Group by 14.4%, and GeekPlus by 11%, indicating strong performance in smaller stocks within the market.
HSI Gains 146 Points at Midday; AI and Pharmaceutical Stocks Surge; KNOWLEDGE ATLAS Jumps 21%
Market Performance: The HSI rose 146 points (0.5%) to 27,173, while the HSCEI and HSTECH also saw gains, with total market turnover reaching HKD133.823 billion.
Tech Stock Movements: Major tech stocks like TENCENT and MEITUAN fell, while others like KUAISHOU and JD-SW experienced gains, indicating mixed performance in the tech sector.
AI and Chip Sector Trends: AI stocks remained in demand, with significant gains for companies like KNOWLEDGE ATLAS and MINIMAX-WP, while chip stocks showed varied results, with SMIC edging up and HUA HONG SEMI dipping.
Pharmaceutical Sector Gains: Drug manufacturers like CSPC PHARMA and INNOVENT BIO saw notable increases in their stock prices, reflecting positive momentum in the pharmaceutical industry.
Midday Update: HSI Ends at 27,173, Gaining 146 Points; HSTI Reaches 5,463, Up 45 Points; MEITUAN Falls Over 3%; YUM CHINA, BOC HONG KONG, HSBC HOLDINGS, DAHSING BANKING, and KB LAMINATES Achieve New Highs
Market Performance: The Hang Seng Index (HSI) rose by 146 points (0.5%) to 27,173, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains of 45 points (0.8%) and 71 points (0.8%) respectively.
Active Heavyweights: Notable movements included Meituan down 3% to $88.3, Xiaomi up 2% to $35.92, Alibaba up 1.5% to $160.2, and Tencent down 1.1% to $554.
Top Gainers: CSPC Pharma, Wuxi Biologics, and Innovent Biologics were among the top gainers, with increases of 6.3%, 5.6%, and 5.3% respectively, while New Oriental fell by 4.7%.
Significant Moves in Other Stocks: China Literature surged by 15.6%, Vobile Group increased by 13.3%, and Dahsing Banking rose by 7.4%, all hitting new highs, indicating strong market activity in various sectors.
JPM Assigns HKD111 Target Price to INNOVENT BIO; Strategic Alliance with Eli Lilly Exceeds Expectations
Strategic Partnership: INNOVENT BIO has formed a strategic partnership with Eli Lilly to co-develop new biological drugs targeting oncology and immunology globally, as reported by JPMorgan.
Positive Market Reaction: JPMorgan views this collaboration as a significant milestone for INNOVENT BIO, enhancing its reputation as a global biopharmaceutical company and showcasing its strong R&D capabilities.
Stock Performance: Following the announcement, INNOVENT BIO's stock rose by 5.386%, with a short selling ratio of 19.306% and a total short selling amount of $259.46 million.
Analyst Ratings: CICC has raised its earnings forecast for INNOVENT BIO and reaffirmed it as a top pick among Chinese biotech firms, while JPMorgan assigned an Overweight rating with a target price of HKD111.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
HSI Rises by 155 Points Driven by Surge in AI and Pharmaceutical Stocks
Market Performance: The HSI rose by 155 points (0.6%) to close at 27,183, with a total market turnover of HKD234.04 billion. The HSCEI and HSTECH also saw gains, closing at 9,242 and 5,451 respectively.
Tech Stock Movements: Major tech stocks like TENCENT and MEITUAN-W experienced declines of 1.6% and 2.5%, while KUAISHOU-W, JD-SW, and BABA-W saw increases between 1.6% and 1.9%.
AI and Pharma Stocks Surge: AI stocks such as UNISOUND and INSILICO rose significantly, with KNOWLEDGE ATLAS jumping 14.8% after JPMorgan initiated coverage. Pharma stocks also performed well, with CSPC PHARMA and INNOVENT BIO gaining between 4.7% and 5.5%.
Chip Sector Performance: SMIC gained 1.7%, while HUA HONG SEMI dipped 1.2%. Other chip-related stocks like INNOSCIENCE and BIREN TECH saw notable increases, with INNOSCIENCE rising 6.9%.
<Daily Summary> HSI Ends at 27,183, Gaining 155 Points; HSTI Finishes at 5,451, Up 33 Points; CSPC PHARMA Surges Over 5%; ZTO EXPRESS-W, WH GROUP, BOC HONG KONG, WHARF REIC, and HANG LUNG PPT Reach New Peaks; Market Activity Increases
Market Performance: The Hang Seng Index (HSI) rose by 155 points (0.6%) to close at 27,183, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains, with market turnover reaching $234.04 billion.
Active Heavyweights: Notable movements included Meituan down 2.5%, Alibaba up 1.6%, Tencent down 1.6%, and Xiaomi up 1.1%, with significant short selling activity across these stocks.
Top Gainers: CSPC Pharma, Innovent Bio, and Pop Mart were among the top gainers, with CSPC Pharma increasing by 5.5% and Pop Mart by 4.9%, while New Oriental saw a decline of 4.4%.
High Performers in HSMI & HSSI: China Literature surged by 15.4%, Vobile Group by 14.4%, and GeekPlus by 11%, indicating strong performance in smaller stocks within the market.
HSI Gains 146 Points at Midday; AI and Pharmaceutical Stocks Surge; KNOWLEDGE ATLAS Jumps 21%
Market Performance: The HSI rose 146 points (0.5%) to 27,173, while the HSCEI and HSTECH also saw gains, with total market turnover reaching HKD133.823 billion.
Tech Stock Movements: Major tech stocks like TENCENT and MEITUAN fell, while others like KUAISHOU and JD-SW experienced gains, indicating mixed performance in the tech sector.
AI and Chip Sector Trends: AI stocks remained in demand, with significant gains for companies like KNOWLEDGE ATLAS and MINIMAX-WP, while chip stocks showed varied results, with SMIC edging up and HUA HONG SEMI dipping.
Pharmaceutical Sector Gains: Drug manufacturers like CSPC PHARMA and INNOVENT BIO saw notable increases in their stock prices, reflecting positive momentum in the pharmaceutical industry.
Midday Update: HSI Ends at 27,173, Gaining 146 Points; HSTI Reaches 5,463, Up 45 Points; MEITUAN Falls Over 3%; YUM CHINA, BOC HONG KONG, HSBC HOLDINGS, DAHSING BANKING, and KB LAMINATES Achieve New Highs
Market Performance: The Hang Seng Index (HSI) rose by 146 points (0.5%) to 27,173, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains of 45 points (0.8%) and 71 points (0.8%) respectively.
Active Heavyweights: Notable movements included Meituan down 3% to $88.3, Xiaomi up 2% to $35.92, Alibaba up 1.5% to $160.2, and Tencent down 1.1% to $554.
Top Gainers: CSPC Pharma, Wuxi Biologics, and Innovent Biologics were among the top gainers, with increases of 6.3%, 5.6%, and 5.3% respectively, while New Oriental fell by 4.7%.
Significant Moves in Other Stocks: China Literature surged by 15.6%, Vobile Group increased by 13.3%, and Dahsing Banking rose by 7.4%, all hitting new highs, indicating strong market activity in various sectors.
JPM Assigns HKD111 Target Price to INNOVENT BIO; Strategic Alliance with Eli Lilly Exceeds Expectations
Strategic Partnership: INNOVENT BIO has formed a strategic partnership with Eli Lilly to co-develop new biological drugs targeting oncology and immunology globally, as reported by JPMorgan.
Positive Market Reaction: JPMorgan views this collaboration as a significant milestone for INNOVENT BIO, enhancing its reputation as a global biopharmaceutical company and showcasing its strong R&D capabilities.
Stock Performance: Following the announcement, INNOVENT BIO's stock rose by 5.386%, with a short selling ratio of 19.306% and a total short selling amount of $259.46 million.
Analyst Ratings: CICC has raised its earnings forecast for INNOVENT BIO and reaffirmed it as a top pick among Chinese biotech firms, while JPMorgan assigned an Overweight rating with a target price of HKD111.
